Add calcitonin to IV bisphosphonate or denosumab for severe HCM
STEP 1 — Gather Information
Obtain serum calcium (adjusted for albumin), assess symptoms (e.g., polyuria, weakness, confusion), evaluate renal function (eGFR), and check for contraindications to calcitonin (e.g., prior tachyphylaxis). If SCa >14 mg/dL, proceed to Step 2; otherwise, consider alternative diagnoses and manage per mild/moderate HCM guidelines.
STEP 2 — Rule In / Rule Out
Is serum calcium >14 mg/dL? If yes, rule in severe HCM and proceed to Step 3; if no, rule out severe HCM and consider other etiologies or lower-severity HCM pathways.
STEP 3 — Classify or Stratify
Stratify by renal function: if eGFR ≥30 mL/min/1.73m², prefer intravenous bisphosphonate; if eGFR <30 mL/min/1.73m², prefer denosumab with dose adjustment. Proceed to Step 4 with selected agent.
STEP 4 — Decide
Administer calcitonin (salmon calcitonin 4–8 units/kg IM or SC every 6–12 hours) plus the chosen antiresorptive: intravenous bisphosphonate (pamidronate 60–90 mg over 2–24 hours or zoledronic acid 4 mg over 15 minutes) or denosumab 120 mg subcutaneous. Recheck calcium in 12–24 hours.
Clinical Guardrails / Mimics / Pitfalls
Limit calcitonin to 48–72 hours due to tachyphylaxis; monitor serum calcium and phosphorus every 12–24 hours to avoid hypocalcemia; ensure adequate hydration before bisphosphonate; adjust bisphosphonate dose for renal impairment (e.g., pamidronate over 2–24 hours if eGFR <30); denosumab requires vitamin D repletion and calcium supplementation in deficient patients; do not use calcitonin monotherapy; avoid in patients with known salmon polypeptide allergy.
Concrete Clinical Example
A 68-year-old with metastatic lung cancer presents with SCa 15.2 mg/dL, polyuria, and nausea. eGFR is 45 mL/min/1.73m². Give calcitonin 4 units/kg SC every 6 hours plus zoledronic acid 4 mg IV over 15 minutes. After 24 hours, SCa drops to 12.8 mg/dL; continue denosumab 120 mg SC weekly for 3 doses then monthly, discontinuing calcitonin after 60 hours.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621
TODO: consider adding scripts/calc.py for the es-hcm-severe-add-calcitonin-bp-dmab calculator